|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
Chain B:
E.C.2.3.1.-
- ?????
|
|
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
Chain B:
E.C.2.3.1.48
- histone acetyltransferase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
L-lysyl-[protein] + acetyl-CoA = N6-acetyl-L-lysyl-[protein] + CoA + H+
|
 |
 |
 |
 |
 |
L-lysyl-[protein]
|
+
|
acetyl-CoA
|
=
|
N(6)-acetyl-L-lysyl-[protein]
|
+
|
CoA
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Proc Natl Acad Sci U S A
99:5367-5372
(2002)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha.
|
|
S.J.Freedman,
Z.Y.Sun,
F.Poy,
A.L.Kung,
D.M.Livingston,
G.Wagner,
M.J.Eck.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Adaptation to hypoxia is mediated by transactivation of hypoxia-responsive genes
by hypoxia-inducible factor-1 (HIF-1) in complex with the CBP and p300
transcriptional coactivators. We report the solution structure of the
cysteine/histidine-rich 1 (CH1) domain of p300 bound to the C-terminal
transactivation domain of HIF-1 alpha. CH1 has a triangular geometry composed of
four alpha-helices with three intervening Zn(2+)-coordinating centers. CH1
serves as a scaffold for folding of the HIF-1 alpha C-terminal transactivation
domain, which forms a vise-like clamp on the CH1 domain that is stabilized by
extensive hydrophobic and polar interactions. The structure reveals the
mechanism of specific recognition of p300 by HIF-1 alpha, and shows how HIF-1
alpha transactivation is regulated by asparagine hydroxylation.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Fig. 1. Domain structures and sequence alignments of
HIF-1 and p300
and structure of the CTAD/CH1 complex. (a) Functional domains of
CBP/p300 (Upper) and HIF-1 (Lower).
Domains in CBP/p300 are nuclear hormone receptor-binding domain
(Nu), cysteine/histidine-rich domains (CH1, CH2, and CH3),
CREB-binding domain (KIX), bromodomain (Br), histone
acetyltransferase domain (HAT), glutamine-rich domain (Q), and
IRF-3-binding domain (I). The CH1 and CH3 domains are
structurally homologous and also have been termed TAZ1 and TAZ2,
respectively. Domains in HIF-1 are basic
helix-loop-helix domain (bHLH), Per-Arnt-Sim homology domain
(PAS), and N- and C-terminal transactivation domains (NTAD,
CTAD). Transcription factors that have been shown to associate
with CBP/p300 are shown above the interacting domains. Those
that have been structurally characterized in complex with their
respective CBP/p300 binding domains are highlighted in red. The
domains of p300 and HIF-1 that form
the complex studied here are highlighted in dark blue and red,
respectively. This figure was adapted from Vo and Goodman, 2001
(16). (b) The sequence of the human HIF-1 CTAD used
for structure determination (top line) is aligned with the
homologous regions of HIF-1 from other
species and human HIF-2 . Note that
the structured portion of HIF-1 (residues
792-824) is nearly 100% conserved. (b and c) Elements of
secondary structure are indicated above the alignment. The
shaded vertical bars above the alignment indicate the fraction
of the residue surface that is buried in the HIF-1 /p300
complex interface. (c) The sequence of human p300 CH1 used for
structure determination (top line) is aligned with the
homologous regions of p300 and CBP. The single histidine and
three cysteines that form each of the three strictly conserved
Zn2+-binding sites are shaded violet, green, or yellow. Residues
highlighted in blue are conserved residues that form the
hydrophobic core of the human CH1 structure. Most of these
residues are conserved in the CH3 domain. The residues that are
buried in the interface between the HIF-1 CTAD and
p300 CH1 domain are distributed among all four helices but are
most prominent along 3. The
arrowheads under the alignment indicate the positions of
insertions relative to the human p300 CH1 sequence. The number
of residues inserted in the CH3 domains are indicated; those
numbers with asterisks are insertions in the C. elegans sequence
of CBP CH1. The aligned sequences are: h, Homo sapiens; b, Bos
taurus; m, Mus musculus; x, Xenopus laevis; d, Drosophila
melanogaster; c, Caenorhabditis elegans. (d) Stereoview of 17
superimposed CTAD/CH1 complex structures. (e) Ribbon diagram of
the lowest-energy CTAD/CH1 structure. The fold of CH1 (royal
blue/light blue) and CTAD (red/orange) is described in the text.
Helices 1 (residues
332-354), 2 (residues
367-379), 3 (residues
391-405), and 4 (residues
414-418) refer to the -helical
regions of p300 CH1; residues 332-334 are 3:10 helix. Helices
A (residues
797-803) and B (residues
816-822) refer to the -helical
regions of the HIF-1 CTAD;
residues 815-817 are 3:10 helix. Green spheres indicate the
three putative Zn2+ ions in CH1 and are labeled Zn1 through Zn3.
(f) Superposition of the CH1 domain from the CTAD/CH1 complex
with the free CBP CH3 domain (25). Note the similar folds from
1 through
3 (gray)
and the conformational differences of the third Zn2+-binding
turn and 4 (CH1
residues 407-418 in blue and CH3 residues 1835-1850 in yellow).
The eight-residue insertion (residues 353-363) in the first
Zn2+-binding turn of CH1 relative to the homologous region of
CH3 (residues 1788-1790) is similarly color-coded. d was
prepared with MOLMOL (40), e was prepared with MOLSCRIPT (41),
and f was prepared with INSIGHTII (Accelrys).
|
 |
Figure 2.
Fig. 2. Intermolecular contacts between the HIF-1 CTAD and
p300 CH1 domains. (a) A region of the CTAD/CH1 complex is
magnified to illustrate some of the important hydrophobic
contacts that define the topology of the interaction. CTAD wraps
around CH1 like a clamp such that A and B rest in
grooves on either side of 3. Note the
parallel configuration of the CH1 helix sandwiched between the
two CTAD helices. Several hydrophobic side chains considered to
contribute to the binding energy are displayed as sticks and are
labeled by residue and number. (b) A similar region of the
complex (interhelical loop of CTAD, N terminus of 1 and 3 from CH1)
is shown in a different orientation to illustrate putative
intermolecular hydrogen bond contacts that stabilize the
complex. The presence of hydrogen bonds is supported by NOE and
structure analyses. (c and d) The N- and C-terminal regions of
the HIF-1 CTAD (red
ribbon) are shown with the p300 CH1 domain represented as an
accessible surface. The surface is colored by charge and is
scaled from 10 kT/e
(red) to +10 kT/e (blue). Selected HIF-1 side chains
are labeled in black. Basic residues in CH1 are labeled in
white. (e) Position of Asn-803 in the CTAD/CH1 complex indicates
how -hydroxylation
would inhibit binding. CH1 residues are shown in yellow and CTAD
residues are shown in white. The Asn-803 H (pro-R) and
H (pro-S) are
colored green. Van der Waals surfaces are shown for residues
surrounding the Asn-803 side chain. Substitution of either the
pro-R or pro-S -protons
with a hydroxyl group would disfavor complex formation because
of steric and hydrogen-bonding considerations (see text). (a, b,
and e) Complexes were prepared with INSIGHTII (Accelrys). (c and
d) Complexes were prepared with GRASP (42).
|
 |
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
M.N.Khan,
T.Bhattacharyya,
P.Andrikopoulos,
M.A.Esteban,
R.Barod,
T.Connor,
M.Ashcroft,
P.H.Maxwell,
and
S.Kiriakidis
(2011).
Factor inhibiting HIF (FIH-1) promotes renal cancer cell survival by protecting cells from HIF-1α-mediated apoptosis.
|
| |
Br J Cancer,
104,
1151-1159.
|
 |
|
|
|
|
 |
S.H.Li,
Y.S.Chun,
J.H.Lim,
L.E.Huang,
and
J.W.Park
(2011).
von Hippel-Lindau protein adjusts oxygen sensing of the FIH asparaginyl hydroxylase.
|
| |
Int J Biochem Cell Biol,
43,
795-804.
|
 |
|
|
|
|
 |
S.Kushal,
H.Wang,
C.F.László,
L.Z.Szábo,
and
B.Z.Olenyuk
(2011).
Inhibition of hypoxia-inducible transcription factor complex with designed epipolythiodiketopiperazine.
|
| |
Biopolymers,
95,
8.
|
 |
|
|
|
|
 |
J.L.Ruas,
U.Berchner-Pfannschmidt,
S.Malik,
K.Gradin,
J.Fandrey,
R.G.Roeder,
T.Pereira,
and
L.Poellinger
(2010).
Complex regulation of the transactivation function of hypoxia-inducible factor-1 alpha by direct interaction with two distinct domains of the CREB-binding protein/p300.
|
| |
J Biol Chem,
285,
2601-2609.
|
 |
|
|
|
|
 |
K.G.Pringle,
K.L.Kind,
A.N.Sferruzzi-Perri,
J.G.Thompson,
and
C.T.Roberts
(2010).
Beyond oxygen: complex regulation and activity of hypoxia inducible factors in pregnancy.
|
| |
Hum Reprod Update,
16,
415-431.
|
 |
|
|
|
|
 |
L.K.Henchey,
J.R.Porter,
I.Ghosh,
and
P.S.Arora
(2010).
High specificity in protein recognition by hydrogen-bond-surrogate α-helices: selective inhibition of the p53/MDM2 complex.
|
| |
Chembiochem,
11,
2104-2107.
|
 |
|
|
|
|
 |
L.W.Lee,
and
A.K.Mapp
(2010).
Transcriptional switches: chemical approaches to gene regulation.
|
| |
J Biol Chem,
285,
11033-11038.
|
 |
|
|
|
|
 |
M.Kjaergaard,
K.Teilum,
and
F.M.Poulsen
(2010).
Conformational selection in the molten globule state of the nuclear coactivator binding domain of CBP.
|
| |
Proc Natl Acad Sci U S A,
107,
12535-12540.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.Koda,
L.Kanczuga-Koda,
M.Sulkowska,
E.Surmacz,
and
S.Sulkowski
(2010).
Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: effects of preoperative chemotherapy.
|
| |
BMC Cancer,
10,
320.
|
 |
|
|
|
|
 |
M.L.Nelson,
H.S.Kang,
G.M.Lee,
A.G.Blaszczak,
D.K.Lau,
L.P.McIntosh,
and
B.J.Graves
(2010).
Ras signaling requires dynamic properties of Ets1 for phosphorylation-enhanced binding to coactivator CBP.
|
| |
Proc Natl Acad Sci U S A,
107,
10026-10031.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Y.Guan,
K.R.Reddy,
Q.Zhu,
Y.Li,
K.Lee,
P.Weerasinghe,
J.Prchal,
G.L.Semenza,
and
N.Jing
(2010).
G-rich oligonucleotides inhibit HIF-1alpha and HIF-2alpha and block tumor growth.
|
| |
Mol Ther,
18,
188-197.
|
 |
|
|
|
|
 |
C.Huang,
Y.Han,
Y.Wang,
X.Sun,
S.Yan,
E.T.Yeh,
Y.Chen,
H.Cang,
H.Li,
G.Shi,
J.Cheng,
X.Tang,
and
J.Yi
(2009).
SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation.
|
| |
EMBO J,
28,
2748-2762.
|
 |
|
|
|
|
 |
D.Shi,
M.S.Pop,
R.Kulikov,
I.M.Love,
A.L.Kung,
A.Kung,
and
S.R.Grossman
(2009).
CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53.
|
| |
Proc Natl Acad Sci U S A,
106,
16275-16280.
|
 |
|
|
|
|
 |
E.Roudier,
and
A.Perrin
(2009).
Considering the role of pyruvate in tumor cells during hypoxia.
|
| |
Biochim Biophys Acta,
1796,
55-62.
|
 |
|
|
|
|
 |
J.Key,
T.H.Scheuermann,
P.C.Anderson,
V.Daggett,
and
K.H.Gardner
(2009).
Principles of ligand binding within a completely buried cavity in HIF2alpha PAS-B.
|
| |
J Am Chem Soc,
131,
17647-17654.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.M.Wojciak,
M.A.Martinez-Yamout,
H.J.Dyson,
and
P.E.Wright
(2009).
Structural basis for recruitment of CBP/p300 coactivators by STAT1 and STAT2 transactivation domains.
|
| |
EMBO J,
28,
948-958.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.Upadhyay,
R.K.Kesharwani,
and
K.Misra
(2009).
Comparative study of antioxidants as cancer preventives through inhibition of HIF-1 alpha activity.
|
| |
Bioinformation,
4,
233-236.
|
 |
|
|
|
|
 |
K.M.Block,
H.Wang,
L.Z.Szabó,
N.W.Polaske,
L.K.Henchey,
R.Dubey,
S.Kushal,
C.F.László,
J.Makhoul,
Z.Song,
E.J.Meuillet,
and
B.Z.Olenyuk
(2009).
Direct inhibition of hypoxia-inducible transcription factor complex with designed dimeric epidithiodiketopiperazine.
|
| |
J Am Chem Soc,
131,
18078-18088.
|
 |
|
|
|
|
 |
K.M.Cook,
S.T.Hilton,
J.Mecinovic,
W.B.Motherwell,
W.D.Figg,
and
C.J.Schofield
(2009).
Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism.
|
| |
J Biol Chem,
284,
26831-26838.
|
 |
|
|
|
|
 |
L.Kelly,
M.A.McDonough,
M.L.Coleman,
P.J.Ratcliffe,
and
C.J.Schofield
(2009).
Asparagine beta-hydroxylation stabilizes the ankyrin repeat domain fold.
|
| |
Mol Biosyst,
5,
52-58.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.E.Cockman,
J.D.Webb,
and
P.J.Ratcliffe
(2009).
FIH-dependent asparaginyl hydroxylation of ankyrin repeat domain-containing proteins.
|
| |
Ann N Y Acad Sci,
1177,
9.
|
 |
|
|
|
|
 |
M.Miller
(2009).
The importance of being flexible: the case of basic region leucine zipper transcriptional regulators.
|
| |
Curr Protein Pept Sci,
10,
244-269.
|
 |
|
|
|
|
 |
S.E.Wilkins,
J.Hyvärinen,
J.Chicher,
J.J.Gorman,
D.J.Peet,
R.L.Bilton,
and
P.Koivunen
(2009).
Differences in hydroxylation and binding of Notch and HIF-1alpha demonstrate substrate selectivity for factor inhibiting HIF-1 (FIH-1).
|
| |
Int J Biochem Cell Biol,
41,
1563-1571.
|
 |
|
|
|
|
 |
S.Fukuchi,
K.Homma,
Y.Minezaki,
T.Gojobori,
and
K.Nishikawa
(2009).
Development of an accurate classification system of proteins into structured and unstructured regions that uncovers novel structural domains: its application to human transcription factors.
|
| |
BMC Struct Biol,
9,
26.
|
 |
|
|
|
|
 |
W.Feng,
F.Ye,
W.Xue,
Z.Zhou,
and
Y.J.Kang
(2009).
Copper regulation of hypoxia-inducible factor-1 activity.
|
| |
Mol Pharmacol,
75,
174-182.
|
 |
|
|
|
|
 |
Z.K.Otrock,
H.A.Hatoum,
A.H.Awada,
R.S.Ishak,
and
A.I.Shamseddine
(2009).
Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives.
|
| |
Crit Rev Oncol Hematol,
70,
93.
|
 |
|
|
|
|
 |
A.G.Turjanski,
J.S.Gutkind,
R.B.Best,
and
G.Hummer
(2008).
Binding-induced folding of a natively unstructured transcription factor.
|
| |
PLoS Comput Biol,
4,
e1000060.
|
 |
|
|
|
|
 |
A.J.Filiano,
C.D.Bailey,
J.Tucholski,
S.Gundemir,
and
G.V.Johnson
(2008).
Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling.
|
| |
FASEB J,
22,
2662-2675.
|
 |
|
|
|
|
 |
F.S.Lee
(2008).
Genetic causes of erythrocytosis and the oxygen-sensing pathway.
|
| |
Blood Rev,
22,
321-332.
|
 |
|
|
|
|
 |
G.Xenaki,
T.Ontikatze,
R.Rajendran,
I.J.Stratford,
C.Dive,
M.Krstic-Demonacos,
and
C.Demonacos
(2008).
PCAF is an HIF-1alpha cofactor that regulates p53 transcriptional activity in hypoxia.
|
| |
Oncogene,
27,
5785-5796.
|
 |
|
|
|
|
 |
H.S.Kang,
M.L.Nelson,
C.D.Mackereth,
M.Schärpf,
B.J.Graves,
and
L.P.McIntosh
(2008).
Identification and structural characterization of a CBP/p300-binding domain from the ETS family transcription factor GABP alpha.
|
| |
J Mol Biol,
377,
636-646.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.Lisy,
and
D.J.Peet
(2008).
Turn me on: regulating HIF transcriptional activity.
|
| |
Cell Death Differ,
15,
642-649.
|
 |
|
|
|
|
 |
K.Salnikow,
and
A.Zhitkovich
(2008).
Genetic and epigenetic mechanisms in metal carcinogenesis and cocarcinogenesis: nickel, arsenic, and chromium.
|
| |
Chem Res Toxicol,
21,
28-44.
|
 |
|
|
|
|
 |
R.Chowdhury,
A.Hardy,
and
C.J.Schofield
(2008).
The human oxygen sensing machinery and its manipulation.
|
| |
Chem Soc Rev,
37,
1308-1319.
|
 |
|
|
|
|
 |
S.Kaluz,
M.Kaluzová,
and
E.J.Stanbridge
(2008).
Does inhibition of degradation of hypoxia-inducible factor (HIF) alpha always lead to activation of HIF? Lessons learnt from the effect of proteasomal inhibition on HIF activity.
|
| |
J Cell Biochem,
104,
536-544.
|
 |
|
|
|
|
 |
S.Kaluz,
M.Kaluzová,
and
E.J.Stanbridge
(2008).
Regulation of gene expression by hypoxia: integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element.
|
| |
Clin Chim Acta,
395,
6.
|
 |
|
|
|
|
 |
T.Klimova,
and
N.S.Chandel
(2008).
Mitochondrial complex III regulates hypoxic activation of HIF.
|
| |
Cell Death Differ,
15,
660-666.
|
 |
|
|
|
|
 |
Y.H.Chen,
L.M.Comeaux,
S.J.Eyles,
and
M.J.Knapp
(2008).
Auto-hydroxylation of FIH-1: an Fe(ii), alpha-ketoglutarate-dependent human hypoxia sensor.
|
| |
Chem Commun (Camb),
(),
4768-4770.
|
 |
|
|
|
|
 |
Y.Li,
T.Kimura,
R.W.Huyck,
J.H.Laity,
and
G.K.Andrews
(2008).
Zinc-induced formation of a coactivator complex containing the zinc-sensing transcription factor MTF-1, p300/CBP, and Sp1.
|
| |
Mol Cell Biol,
28,
4275-4284.
|
 |
|
|
|
|
 |
A.B.Johnson,
and
M.C.Barton
(2007).
Hypoxia-induced and stress-specific changes in chromatin structure and function.
|
| |
Mutat Res,
618,
149-162.
|
 |
|
|
|
|
 |
A.Ozer,
and
R.K.Bruick
(2007).
Non-heme dioxygenases: cellular sensors and regulators jelly rolled into one?
|
| |
Nat Chem Biol,
3,
144-153.
|
 |
|
|
|
|
 |
D.P.Teufel,
S.M.Freund,
M.Bycroft,
and
A.R.Fersht
(2007).
Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53.
|
| |
Proc Natl Acad Sci U S A,
104,
7009-7014.
|
 |
|
|
|
|
 |
E.L.Bell,
T.A.Klimova,
J.Eisenbart,
C.T.Moraes,
M.P.Murphy,
G.R.Budinger,
and
N.S.Chandel
(2007).
The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production.
|
| |
J Cell Biol,
177,
1029-1036.
|
 |
|
|
|
|
 |
J.Li,
E.Wang,
S.Dutta,
J.S.Lau,
S.W.Jiang,
K.Datta,
and
D.Mukhopadhyay
(2007).
Protein kinase C-mediated modulation of FIH-1 expression by the homeodomain protein CDP/Cut/Cux.
|
| |
Mol Cell Biol,
27,
7345-7353.
|
 |
|
|
|
|
 |
K.Sugase,
J.C.Lansing,
H.J.Dyson,
and
P.E.Wright
(2007).
Tailoring relaxation dispersion experiments for fast-associating protein complexes.
|
| |
J Am Chem Soc,
129,
13406-13407.
|
 |
|
|
|
|
 |
Q.Yan,
S.Bartz,
M.Mao,
L.Li,
and
W.G.Kaelin
(2007).
The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo.
|
| |
Mol Cell Biol,
27,
2092-2102.
|
 |
|
|
|
|
 |
A.Huwiler,
and
J.Pfeilschifter
(2006).
Hypoxia and lipid signaling.
|
| |
Biol Chem,
387,
1321-1328.
|
 |
|
|
|
|
 |
C.Hebert,
K.Norris,
P.Parashar,
R.A.Ord,
N.G.Nikitakis,
and
J.J.Sauk
(2006).
Hypoxia-inducible factor-1alpha polymorphisms and TSC1/2 mutations are complementary in head and neck cancers.
|
| |
Mol Cancer,
5,
3.
|
 |
|
|
|
|
 |
C.J.Anderson,
S.F.Hoare,
M.Ashcroft,
A.E.Bilsland,
and
W.N.Keith
(2006).
Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms.
|
| |
Oncogene,
25,
61-69.
|
 |
|
|
|
|
 |
D.G.Nagle,
and
Y.D.Zhou
(2006).
Natural product-derived small molecule activators of hypoxia-inducible factor-1 (HIF-1).
|
| |
Curr Pharm Des,
12,
2673-2688.
|
 |
|
|
|
|
 |
D.Jung,
Y.Choi,
and
M.Uesugi
(2006).
Small organic molecules that modulate gene transcription.
|
| |
Drug Discov Today,
11,
452-457.
|
 |
|
|
|
|
 |
D.M.Fath,
X.Kong,
D.Liang,
Z.Lin,
A.Chou,
Y.Jiang,
J.Fang,
J.Caro,
and
N.Sang
(2006).
Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha.
|
| |
J Biol Chem,
281,
13612-13619.
|
 |
|
|
|
|
 |
G.L.Semenza
(2006).
Development of novel therapeutic strategies that target HIF-1.
|
| |
Expert Opin Ther Targets,
10,
267-280.
|
 |
|
|
|
|
 |
M.Ohh
(2006).
Ubiquitin pathway in VHL cancer syndrome.
|
| |
Neoplasia,
8,
623-629.
|
 |
|
|
|
|
 |
S.Kaluz,
M.Kaluzová,
and
E.J.Stanbridge
(2006).
Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain.
|
| |
Mol Cell Biol,
26,
5895-5907.
|
 |
|
|
|
|
 |
Z.Khan,
G.K.Michalopoulos,
and
D.B.Stolz
(2006).
Peroxisomal localization of hypoxia-inducible factors and hypoxia-inducible factor regulatory hydroxylases in primary rat hepatocytes exposed to hypoxia-reoxygenation.
|
| |
Am J Pathol,
169,
1251-1269.
|
 |
|
|
|
|
 |
D.E.Merry
(2005).
Animal models of Kennedy disease.
|
| |
NeuroRx,
2,
471-479.
|
 |
|
|
|
|
 |
H.J.Dyson,
and
P.E.Wright
(2005).
Intrinsically unstructured proteins and their functions.
|
| |
Nat Rev Mol Cell Biol,
6,
197-208.
|
 |
|
|
|
|
 |
J.L.Ruas,
and
L.Poellinger
(2005).
Hypoxia-dependent activation of HIF into a transcriptional regulator.
|
| |
Semin Cell Dev Biol,
16,
514-522.
|
 |
|
|
|
|
 |
K.Salnikow,
and
K.S.Kasprzak
(2005).
Ascorbate depletion: a critical step in nickel carcinogenesis?
|
| |
Environ Health Perspect,
113,
577-584.
|
 |
|
|
|
|
 |
L.H.Kasper,
F.Boussouar,
K.Boyd,
W.Xu,
M.Biesen,
J.Rehg,
T.A.Baudino,
J.L.Cleveland,
and
P.K.Brindle
(2005).
Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression.
|
| |
EMBO J,
24,
3846-3858.
|
 |
|
|
|
|
 |
N.Sánchez-Puig,
D.B.Veprintsev,
and
A.R.Fersht
(2005).
Binding of natively unfolded HIF-1alpha ODD domain to p53.
|
| |
Mol Cell,
17,
11-21.
|
 |
|
|
|
|
 |
T.Gaber,
R.Dziurla,
R.Tripmacher,
G.R.Burmester,
and
F.Buttgereit
(2005).
Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do!
|
| |
Ann Rheum Dis,
64,
971-980.
|
 |
|
|
|
|
 |
W.G.Kaelin
(2005).
Proline hydroxylation and gene expression.
|
| |
Annu Rev Biochem,
74,
115-128.
|
 |
|
|
|
|
 |
B.K.McColl,
S.A.Stacker,
and
M.G.Achen
(2004).
Molecular regulation of the VEGF family -- inducers of angiogenesis and lymphangiogenesis.
|
| |
APMIS,
112,
463-480.
|
 |
|
|
|
|
 |
B.L.Sopher,
P.S.Thomas,
M.A.LaFevre-Bernt,
I.E.Holm,
S.A.Wilke,
C.B.Ware,
L.W.Jin,
R.T.Libby,
L.M.Ellerby,
and
A.R.La Spada
(2004).
Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration.
|
| |
Neuron,
41,
687-699.
|
 |
|
|
|
|
 |
C.J.Schofield,
and
P.J.Ratcliffe
(2004).
Oxygen sensing by HIF hydroxylases.
|
| |
Nat Rev Mol Cell Biol,
5,
343-354.
|
 |
|
|
|
|
 |
F.R.Sharp,
and
M.Bernaudin
(2004).
HIF1 and oxygen sensing in the brain.
|
| |
Nat Rev Neurosci,
5,
437-448.
|
 |
|
|
|
|
 |
F.R.Sharp,
R.Ran,
A.Lu,
Y.Tang,
K.I.Strauss,
T.Glass,
T.Ardizzone,
and
M.Bernaudin
(2004).
Hypoxic preconditioning protects against ischemic brain injury.
|
| |
NeuroRx,
1,
26-35.
|
 |
|
|
|
|
 |
H.Kiyosawa,
T.Kawashima,
D.Silva,
N.Petrovsky,
Y.Hasegawa,
K.Sakai,
and
Y.Hayashizaki
(2004).
Systematic genome-wide approach to positional candidate cloning for identification of novel human disease genes.
|
| |
Intern Med J,
34,
79-90.
|
 |
|
|
|
|
 |
K.S.Hewitson,
and
C.J.Schofield
(2004).
The HIF pathway as a therapeutic target.
|
| |
Drug Discov Today,
9,
704-711.
|
 |
|
|
|
|
 |
M.Koshiji,
Y.Kageyama,
E.A.Pete,
I.Horikawa,
J.C.Barrett,
and
L.E.Huang
(2004).
HIF-1alpha induces cell cycle arrest by functionally counteracting Myc.
|
| |
EMBO J,
23,
1949-1956.
|
 |
|
|
|
|
 |
B.D.Nguyen,
K.L.Abbott,
K.Potempa,
M.S.Kobor,
J.Archambault,
J.Greenblatt,
P.Legault,
and
J.G.Omichinski
(2003).
NMR structure of a complex containing the TFIIF subunit RAP74 and the RNA polymerase II carboxyl-terminal domain phosphatase FCP1.
|
| |
Proc Natl Acad Sci U S A,
100,
5688-5693.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
D.Lando,
J.J.Gorman,
M.L.Whitelaw,
and
D.J.Peet
(2003).
Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation.
|
| |
Eur J Biochem,
270,
781-790.
|
 |
|
|
|
|
 |
G.L.Semenza
(2003).
Targeting HIF-1 for cancer therapy.
|
| |
Nat Rev Cancer,
3,
721-732.
|
 |
|
|
|
|
 |
M.Safran,
and
W.G.Kaelin
(2003).
HIF hydroxylation and the mammalian oxygen-sensing pathway.
|
| |
J Clin Invest,
111,
779-783.
|
 |
|
|
|
|
 |
P.J.Erbel,
P.B.Card,
O.Karakuzu,
R.K.Bruick,
and
K.H.Gardner
(2003).
Structural basis for PAS domain heterodimerization in the basic helix--loop--helix-PAS transcription factor hypoxia-inducible factor.
|
| |
Proc Natl Acad Sci U S A,
100,
15504-15509.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.Bhattacharya,
and
P.J.Ratcliffe
(2003).
ExCITED about HIF.
|
| |
Nat Struct Biol,
10,
501-503.
|
 |
|
|
|
|
 |
S.J.Freedman,
Z.Y.Sun,
A.L.Kung,
D.S.France,
G.Wagner,
and
M.J.Eck
(2003).
Structural basis for negative regulation of hypoxia-inducible factor-1alpha by CITED2.
|
| |
Nat Struct Biol,
10,
504-512.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
W.Kim,
and
W.G.Kaelin
(2003).
The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer.
|
| |
Curr Opin Genet Dev,
13,
55-60.
|
 |
|
|
|
|
 |
C.Lee,
J.H.Chang,
H.S.Lee,
and
Y.Cho
(2002).
Structural basis for the recognition of the E2F transactivation domain by the retinoblastoma tumor suppressor.
|
| |
Genes Dev,
16,
3199-3212.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
G.L.Semenza
(2002).
Physiology meets biophysics: visualizing the interaction of hypoxia-inducible factor 1 alpha with p300 and CBP.
|
| |
Proc Natl Acad Sci U S A,
99,
11570-11572.
|
 |
|
|
|
|
 |
W.G.Kaelin
(2002).
Molecular basis of the VHL hereditary cancer syndrome.
|
| |
Nat Rev Cancer,
2,
673-682.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |